clinical trial · NCT07126158
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Pancreatic AdenocarcinomaCancer of the PancreasPancreas CancerPancreatic CancerStereotactic body radiotherapyDefactinibAvutometinib
brief summary
Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.
started
Apr 10, 2026
primary completion
Apr 30, 2030
completion
Apr 30, 2030
last updated
Apr 15, 2026
official title
Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol